MAPT and Dravet syndrome: To characterise the novel DYRK1A inhibitors, DYR219 and DYR533, we compared the effects of overexpression of human Tau (0N4R), human tandem oligomerising secreted Aβ42 and fly mnb-H on degeneration of photoreceptor neurons, longevity, motor performance, sleep and memory measuring the ability of the drugs to suppress these DS and AD relevant phenotypes.